AUPH News and Press, Aurinia Pharmaceuticals Inc From 07/29/22

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) were sliding 6.5% lower as of 11:36 a.m. ET on Wednesday. The stock fell as much as 12.7% earlier in the day. This decline came after Canadian investment bank Bloom Burton & Co. downgraded Aurina stock from a buy recommendation to...

OBsEVA ( OBSV ) -73% on plans for restructuring after setback for uterine fibroids drug. F45 Training Holdings FXLV -57% on slashed guidance, job cuts, CEO exit. Cassava Sciences SAVA -24% on report of criminal probe linked to Alzheimer’s drug....

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (“IPR”) filed...

Potential M&A interest in Aurinia Pharmaceuticals ( NASDAQ: AUPH ) could be hampered -- at least in the short-term -- by a board's review of a patent related to the company's lupus drug Lupkynis (voclosporin), according to Cantor Fitzgerald. Shares are down 7% in l...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4, 2022, before markets open. Aurinia’s management team w...

Hanger ( HNGR ) +25% on deal to be taken private at $1.25B enterprise value. Stronghold Digital Mining ( SDIG ) +21% . Yoshitsu ( TKLF ) +20% enters into definitive agreement to acquire Tokyo Lifestyle Limited. Applied Blockchain ( APLD ...

Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) announced on Friday that an advisory committee of the European Medicines Agency (EMA) issued a positive opinion on its lupus nephritis drug Lupkynis recommending its marketing authorization in the region. The decisi...

Positive CHMP opinion is based on a comprehensive submission including data from the pivotal AURORA 1 efficacy study and the AURORA 2 continuation study, demonstrating voclosporin to be safe and well tolerated for up to three years of treatment. Based on the CHMP recommendatio...

Our next Marketplace Contributor Roundtable Series will be a Q2 Earnings Preview. To kick off, we have responses from 16 Marketplace contributors on Tech and Growth stocks. The series continues next week with everything from Dividends to Value Stocks and Macro coverage. As alw...